magneticmagic - online magnetic jewelry

A new HAY FEVER breakthrough clinically proven to reduce allergy symptoms and antihistamine use. How long were symptoms reduced? Studies showed a one-year reduction. How long? Yes, one year! this medication is a lozenge taken twice daily for 21 days. this medication is non-drowsy, natural and available without a prescription. this medication is a 21 day treatment. this medication users report reductions in symptoms one year after completing the treatment without taking additional this medication. How long? Yes one year, compared to 24-hour antihistamines it''s much longer lasting. Patients known to have seasonal allergy were examined in clinical studies in five U.S. states by qualified medical doctors. magneticmagic Each patient was given either the real this medication or a placebo (a dummy treatment). Nobody knew who got what. Patients recorded in symptons diaries how bad their symptoms were during and after the treatment. About one year later, patients completed a second diary. 64% of the group of patients receiving this medication recorded less sneezing, runny nose and nasal congestion one year after completing the treatment in a clinical study. This compares to 35% of the placebo group.

Antihistamines As the name indicates, an antihistamine counters the effects of histamine, which is released magneticmagic by the mast cells in the body''s tissues and contributes to allergy symptoms. For many years, antihistamines have proven useful in relieving sneezing and itching in the nose, throat, and eyes and in reducing nasal swelling and drainage. Many people who take antihistamines experience some distressing side effects: drowsiness and loss of alertness and coordination. In children, such reactions can be misinterpreted as behavior problems. During the last few years, however, antihistamines that cause fewer of these side effects have become available by prescription. These new nonsedating antihistamines are as effective as other antihistamines in preventing histamine-induced symptoms, but do so without causing sleepiness.

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6